Fish oil and evening primrose oil have ameliorative effects on obesity-associated complications in olanzapine-administered rats

Abstract

Olanzapine is an atypical antipsychotic medication utilized for the management of schizophrenia and bipolar disorder. Obesity is a negative consequence of olanzapine. Fish Oil (FO) and Evening Primrose Oil (EPO), are proposed to possess anti-obesity properties. The present study sought to examine the impacts of these oils on olanzapine-induced obesity and its associated abnormalities in female albino rats. The animals were categorized into four groups designated Normal, Oanzapine, Olanzapine + FO (200 mg/kg, oral) and Olanzapine + EPO (200 mg/kg, oral) groups. All animals, except the normal control group, were orally given olanzapine at a dosage of 4 mg/kg/day for 8 weeks and the treated groups started during the last 4 weeks. Body weight variations were observed on a weekly basis during the investigation. Upon the end of the trial, serum samples were obtained for detection of various biochemical and physiological parameters and pancreas and omental adipose tissues were dissected out for histological analysis. The data of the study indicated a substantial increase in serum concentrations of all mentioned biochemical parameters except serum levels insulin and C-peptide, which exhibited a significant decrease in olanzapine-induced obese rats in comparison with the normal control. After treatments on olanzapine-administered rats with these oils, body weight gains and adipose tissue absolute and relative weights were significantly improved. Serum fasting and postprandial glucose levels, insulin, lipid profile, and enzymes related to liver function were also significantly ameliorated. Thereby, these findings indicated the potential of FO and EPO to control obesity and reduce obesity-related olanzapine complications.